2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

European journal of nuclear medicine and molecular imaging, 2021-07, Vol.48 (7), p.2121-2139 [Peer Reviewed Journal]

The Author(s) 2021 ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1619-7070 ;ISSN: 1619-7089 ;EISSN: 1619-7089 ;DOI: 10.1007/s00259-021-05258-7 ;PMID: 33674895

Full text available